For Professionals

by Jack Lewin, M.D.

DMR Therapy delivered at the Diabetes Treatment Centers of America (DTCA), and affiliated U.S. Alliance of Diabetes Treatment Centers elsewhere in the United States, has been substantiated by compelling observational studies, but double-blind and/or unbiased studies with treatment and control groups are needed to fully understand and document the remarkable reported outcome improvements in quality of life and in arresting or reversing the common co-morbidities of diabetes with DMRT. 

DMRT does not cure diabetes. It positively impacts the underlying metabolic causes of the major complications of diabetes.

The consequences and costs of diabetes to patients, and to our society, are truly devastating. 

Contrary to recent reports by blogger Cheryl Clark in MedPage, this form of insulin therapy, delivering insulin in pulses as the pancreas does naturally, is not the sole invention of Trina Health and its charismatic founder, Ford Gilbert. He did develop a protocol that successfully reversed the distress and frequent hospitalizations of his very ill daughter, Trina, who suffered with T1 Diabetes. 

But other protocols are also in use in clinics across America and internationally.

That said, the alleged charges against Ford Gilbert have no relevance to pulsatile insulin infusion therapy as Ms. Clark implies. 

What is relevant, are the benefits of this therapy for patients suffering from diabetic retinopathy and macular edema, neuropathy of the hands and feet, wounds that won't heal, kidney and cardiovascular complications, and chronic mental and physical fatigue due to diabetes. 

Today's conventional therapy for diabetes of delivering sustained insulin is not having the hoped-for impact on patients’ quality of life, nor producing the anticipated cost savings.

 Instead increasing morbidity and mortality and runaway costs of diabetes indicate that we need to open our minds to therapeutic alternatives.

For questions to Dr. Jack Lewin, you can contact him via email at:

by Elliot Justin, M.D., FACEP

Various versions and protocols of the pulsatile insulin infusion (PII) therapy have been tested and referenced in the literature dating back to the 1930s, but well-designed and unbiased clinical trials with control groups are indicated and in process. 

The following studies represent the evolution of the scientific basis of pulsatile therapy:

  • 1983-Matthews-Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes 32(7) 617-621
  • 1986-Komjatii-Pulsatile insulin superior to continuous on hepatic glucose production. Endocrinology 118(1):312-319
  • 1990-Paolisso-Pulsatile insulin therapy delivery has greater metabolic effects than continuous hormone administration in man: Importance of pulse frequency. Diabetes 61:2269-2279
  • 2000-Dailey-Effects of pulsatile insulin therapy on the progression of diabetic nephropathy. Metabolism 49(11): 1491-1495
  • 2009-Mirbolooki-Pulsatile intravenous insulin therapy: the best practice to reverse diabetic complications? Medical Hypotheses 73:363-369
  • 2010-Weinrauch-Pulsatile intermittent insulin therapy for attenuation of retinopathy. Metabolism 59(10):1429-1434
  • 2012-Matveyenko-Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes 61:2269-2279
  • 2012-Satin-Pulsatile insulin secretion, impaired glucose tolerance and type 2 Diabetes-Molecular Aspects of Medicine 42 (2015) 61-77
  • 2012-Wahrens-Loss of pulsatile insulin secretion: A factor in the pathogenesis of Type 2 diabetes-Diabetes 61(9): 2228-9
  • 2017-Elliott-Microburst insulin infusion: Results of observational studies-Carbohydrate metabolism, painful diabetic neuropathy, and hospital/emergency department      utilization. J. Diabetes Metabolic Disorder Control 4(4): 00118

In my personal and in-depth investigation of the therapy, prior to my becoming the Chief Medical Officer of the DTCA, I reviewed many medical studies and visited seven centers. I was performing an independent analysis based on my years of experience as a practicing physician and founder and leader of several health care enterprises in both technology and service sectors. 

I was impressed and intrigued by the 2017 retrospective paper involving 1,900 patients. It reported an extraordinary alleviation of neuropathy and decrease in ER use and hospitalizations. 

I interviewed doctors, nurse practitioners, and patients. Consistently, I heard remarkable testimonials to the benefits of pulsed insulin.

We at DTCA along with the USDTA will be conducting several prospective papers to define and evaluate the therapy. 

These papers will observe scrupulous standards and be subject to independent evaluation of experts in the field.

Meanwhile, for those who are alarmed by Cheryl Clark’s one-sided, myopic “scare” editorialism, bear in mind that this therapy is safe. 

There are no credible reports of harm, as long as patients continue with their regularly prescribed medications.

For questions to Dr. Elliot Justin, you can contact him via email at: